| scholarly article | Q13442814 |
| P2093 | author name string | Romano Danesi | |
| Manuela Schmidinger | |||
| P2860 | cites work | Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism | Q70822009 |
| Expression of c-kit and kit ligand proteins in normal human tissues | Q71651016 | ||
| Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis | Q74191318 | ||
| Interactions between scatter factors and their receptors: hints for therapeutic applications | Q77373979 | ||
| Beta blockade induces apoptosis in cultured capillary endothelial cells | Q78481480 | ||
| Double-blind, randomized evaluation of clinical efficacy and tolerability of an apple pectin-chamomile extract in children with unspecific diarrhea | Q80060382 | ||
| Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro | Q81735598 | ||
| Usefulness of oral medroxyprogesterone acetate in the management of cancer-related cachexia-anorexia syndrome | Q84145037 | ||
| Exercise for the management of cancer-related fatigue in adults | Q24202860 | ||
| Drug therapy for the management of cancer-related fatigue | Q24234267 | ||
| Interventions for preventing oral mucositis for patients with cancer receiving treatment | Q24235217 | ||
| Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 | ||
| Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study | Q24653016 | ||
| Met in urological cancers | Q26864988 | ||
| Interstitial cells of cajal as pacemakers in the gastrointestinal tract | Q28295738 | ||
| Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2 | Q28487568 | ||
| Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors | Q29615445 | ||
| Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis | Q30250303 | ||
| Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas | Q30278053 | ||
| Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). | Q33416688 | ||
| A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer | Q33434042 | ||
| Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study | Q33441170 | ||
| Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study | Q33465649 | ||
| Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor | Q33684042 | ||
| Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors | Q33698419 | ||
| Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial | Q33946929 | ||
| Molecular pathways leading to cancer cachexia | Q33990203 | ||
| Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients | Q34064299 | ||
| Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC) | Q34077272 | ||
| Safety Profile and Clinical Recommendations for the Use of Lapatinib | Q34096239 | ||
| Pharmacokinetics and pharmacodynamics of cannabinoids | Q34185013 | ||
| Cabozantinib in progressive medullary thyroid cancer | Q34185084 | ||
| Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers | Q34188661 | ||
| Cytokine-induced sickness behavior: where do we stand? | Q34190014 | ||
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 | ||
| The effects of loperamide, or loperamide plus simethicone, on the distribution of gut water as assessed by MRI in a mannitol model of secretory diarrhoea | Q34267861 | ||
| Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? | Q34275520 | ||
| Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. | Q34318170 | ||
| Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Q34495684 | ||
| Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy | Q34571492 | ||
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 | ||
| Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens | Q34591403 | ||
| Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma | Q34683212 | ||
| FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? | Q35048217 | ||
| VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer | Q35112894 | ||
| Distinguishing fatigue and depression in patients with cancer. | Q35581860 | ||
| Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis | Q35640953 | ||
| Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo | Q35746501 | ||
| Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma | Q35943769 | ||
| Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model | Q35954738 | ||
| Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer | Q36128435 | ||
| Cutaneous side-effects of kinase inhibitors and blocking antibodies | Q36181698 | ||
| Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. | Q36281483 | ||
| Managing patients treated with bevacizumab combination therapy. | Q36319038 | ||
| The role of immune cells in the tumor microenvironment. | Q36446771 | ||
| Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment. | Q36656536 | ||
| Fatigue and gene expression in human leukocytes: increased NF-κB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue | Q36701431 | ||
| Updated clinical practice guidelines for the prevention and treatment of mucositis | Q36712445 | ||
| Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer | Q36822111 | ||
| NCCN Task Force Report. prevention and management of mucositis in cancer care. | Q37090657 | ||
| Antiangiogenic drugs and tyrosine kinases. | Q37184709 | ||
| The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway | Q37239237 | ||
| Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. | Q37263768 | ||
| Receptor tyrosine kinase inhibitors in thyroid cancer. | Q37337515 | ||
| Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression | Q37353319 | ||
| Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma | Q37694047 | ||
| Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice | Q37760950 | ||
| Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse | Q37861659 | ||
| c-MET as a potential therapeutic target and biomarker in cancer | Q37962905 | ||
| Guidance on the management of diarrhoea during cancer chemotherapy | Q38245875 | ||
| Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients | Q38336764 | ||
| Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. | Q38410039 | ||
| A phase I study of cabozantinib (XL184) in patients with renal cell cancer. | Q38430335 | ||
| Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis | Q38667071 | ||
| Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients | Q38803271 | ||
| Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma | Q38835745 | ||
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. | Q38859789 | ||
| Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. | Q38892734 | ||
| Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib | Q38979283 | ||
| Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth | Q39472261 | ||
| The tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma model. | Q39601580 | ||
| Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells | Q39745680 | ||
| Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. | Q40483550 | ||
| Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial | Q40483555 | ||
| Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. | Q41099660 | ||
| Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma | Q42400150 | ||
| Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase | Q42450205 | ||
| Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients | Q43121736 | ||
| An evaluation of ondansetron binding interactions with human cytochrome P450 enzymes CYP3A4 and CYP2D6. | Q43143163 | ||
| Tannin-rich carob pod for the treatment of acute-onset diarrhea | Q43314262 | ||
| Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue | Q43494884 | ||
| Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. | Q43731450 | ||
| Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells | Q43997195 | ||
| Intravenous Ondansetron and the QT Interval in Adult Emergency Department Patients: An Observational Study | Q45024374 | ||
| Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib | Q45027232 | ||
| VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature | Q46231250 | ||
| Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults | Q46252268 | ||
| Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse | Q46471088 | ||
| Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib | Q46542862 | ||
| The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin | Q46664297 | ||
| The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. | Q48359202 | ||
| Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. | Q48484700 | ||
| Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. | Q54151586 | ||
| Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. | Q54765102 | ||
| Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. | Q55060584 | ||
| Role of c-kit ligand in the expansion of human hematopoietic progenitor cells | Q67894930 | ||
| P577 | publication date | 2017-11-16 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma |
| Q57481747 | Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma |
| Q55317776 | Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England. |
Search more.